Stock comparison
JOHNSON & JOHNSON is 429.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($618.61 B vs $1.44 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 429.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($618.61 B vs $1.44 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 429.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($618.61 B vs $1.44 B).
Revenue leader
JNJ
XERS: $291.85M vs JNJ: $94.19B.
Profit leader
JNJ
XERS: $554.00K vs JNJ: $26.80B.
Margin leader
JNJ
XERS: 0.2% vs JNJ: 28.5% net margin.
| Metric | XERS | JNJ |
|---|---|---|
| Market cap | $1.44 B | $618.61 B |
| US-listed rank | #2387 | #18 |
| Revenue (latest FY) | $291.85M | $94.19B |
| Net income (latest FY) | $554.00K | $26.80B |
| Net margin | 0.2% | 28.5% |
| P/E (trailing FY) | 2599.0x | 23.1x |
| SEC filings | 290 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 429.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($618.61 B vs $1.44 B).
In their latest fiscal years, Xeris Biopharma Holdings, Inc. reported $291.85M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Xeris Biopharma Holdings, Inc. and JOHNSON & JOHNSON, or browse the full rankings.